Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 15Pemetrexed 15Cisplatin 12Nivolumab 9Carboplatin 8Ipilimumab 7tazemetostat 3fludarabine 3anetumab ravtansine 3Cyclophosphamide 3spartalizumab 2budigalimab 2belinostat 2atezolizumab 2amatuximab 2Vinorelbine 2Paclitaxel 2Gemcitabine 2Docetaxel 2venetoclax 1vandetanib 1trametinib 1tocilizumab 1tislelizumab 1sotorasib 1ruxolitinib 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma × LY3023414 × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡